Vaxart, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate
Vaxart, Inc. (VXRT) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate of 0.00% for the 12-month period ending 2018-12-31, per its 10-K filed 2019-02-06.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate · last filed 2019-02-06
- Vaxart, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2015-09-30 was 0.00%.
- Vaxart, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2014-09-30 was 0.00%.
- Vaxart, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2013-09-30 was 0.00%.
- Vaxart, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2018 was 0.00%.
- Vaxart, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2017 was 0.00%.
- Vaxart, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2015 was 0.00%.
- Vaxart, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2014 was 0.00%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 0 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 12 month |
|---|---|---|---|---|---|
| 2018-12-31 | 0.00% 10-K · filed 2019-02-06 | ||||
| 2018-09-30 | 0.00% 10-Q · filed 2018-11-13 | ||||
| 2018-06-30 | 0.00% 10-Q · filed 2018-08-10 | ||||
| 2017-12-31 | 0.00% 10-K · filed 2019-02-06 | ||||
| 2017-09-30 | 0.00% 10-Q · filed 2018-11-13 | ||||
| 2017-06-30 | 0.00% 10-Q · filed 2018-08-10 | ||||
| 2015-09-30 | 0.00% 10-Q · filed 2015-11-06 | ||||
| 2015-06-30 | 0.00% 10-K · filed 2015-09-11 | ||||
| 2014-09-30 | 0.00% 10-Q · filed 2015-11-06 | ||||
| 2014-06-30 | 0.00% 10-K · filed 2015-09-11 | ||||
| 2013-09-30 | 0.00% 10-Q · filed 2014-11-07 | ||||
| 2013-06-30 | 0.00% 10-K · filed 2015-09-11 | ||||
| 2012-12-31 | 0.00% 10-Q · filed 2013-02-11 | ||||
| 2012-11-12 | 0.00% 10-Q · filed 2013-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B |